In conclusion, our study shows that, compared to previously reported studies, the incidence of MYD88 L265P and PIM1 p.G28A mutations in patients with DLBCL is lower and give a clear picture of the mutational landscape in DLBCL, which may lead to novel ideas for treating the condition. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.